Enhance Security of supply Medication shortages are not just a pharmacy problem; addressing shortages requires action on multiple fronts. But in the meantime healthcare provider organizations must have the right protocols , technology and systems in place to manage drug shortages. Many healthcare provider´s supply chains are not supporting good management of medicines shortages.
BD
BECTON DICKINSON
Company · Spain · EU Transparency Register 196359321438-80
3
positions filed
in the 665 files tracked
3
legislative files
of 665 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,800 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1212 companies & groups on this site, they rank #470 by legislative files engaged, a count of participation, not a measure of influence.
0.9
declared lobbying FTE
self-declared
€200K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2016
in the register since
Declares membership of
- MedTech Europe →
- European Alliance for Access to Safe Medicines (EAASM)
- European Cancer Organization (ECO)
- Federation of European Academies of Medicine (FEAM)
- European Patient Safety Foundation (EUPSF)
- European Sepsis Alliance
Self-declared to the EU Transparency Register (snapshot 15 Oct 2026).
- Register category
- Companies & groups
- Registered as
- Becton Dickinson (BD)
- Head office
- New Jersey, United states
- EU office
- Eysins
Self-declared to the EU Transparency Register (snapshot 15 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track BECTON in PolicySpeak: request access →
Work at BECTON DICKINSON? so we know who speaks for it.
Their record over time
BECTON DICKINSON filed 3 positions between 5 Apr 2021 and 17 May 2026, across 3 of the 665 legislative files tracked here, attaching a full position paper 1 time.
2021 · 1 filed2022 · 1 filed2026 · 1 filed
What they argued
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to healthcare.
Timely diagnosis and appropriate management of Peripheral Arterial Disease (PAD) are essential to improve outcomes, including reduced risk of amputation, cardiovascular events, and death, and improved physical function and quality of life.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put BECTON DICKINSON next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 28.
Is this your organization?
Everything on this page comes from BECTON DICKINSON’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.